WO2010015985A1 - Tricyclic alkylaminomethyloxazolidinone derivatives - Google Patents
Tricyclic alkylaminomethyloxazolidinone derivatives Download PDFInfo
- Publication number
- WO2010015985A1 WO2010015985A1 PCT/IB2009/053356 IB2009053356W WO2010015985A1 WO 2010015985 A1 WO2010015985 A1 WO 2010015985A1 IB 2009053356 W IB2009053356 W IB 2009053356W WO 2010015985 A1 WO2010015985 A1 WO 2010015985A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- methoxy
- dihydro
- benzo
- oxazolidin
- Prior art date
Links
- 0 C=*(*C(C*1N)OC1=O)I=I=N Chemical compound C=*(*C(C*1N)OC1=O)I=I=N 0.000 description 11
- HUHZAMBLEKHDBP-UHFFFAOYSA-N NCC(CN1)OC1=O Chemical compound NCC(CN1)OC1=O HUHZAMBLEKHDBP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Definitions
- the present invention concerns tricyclic alkylaminomethyloxazolidinone derivatives, a pharmaceutical antibacterial composition containing them and the use of these compounds in the manufacture of a medicament for the treatment of infections (e.g. bacterial infections).
- infections e.g. bacterial infections
- These compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including among others Gram-positive and Gram-negative aerobic and anaerobic bacteria and mycobacteria.
- Enterobacteriacea are cephalosporin and quinolone resistant;
- microorganisms that are causing persistent infections are increasingly being recognized as causative agents or co factors of severe chronic diseases like peptic ulcers or heart diseases.
- Certain antibacterial compounds comprising both a quinoline or naphthyridine moiety and an oxazolidinone group have been described in WO 2008/026172. In these compounds however, unlike the compounds of formula I described hereafter, the oxazolidinone is part of a spiro group and the quinoline or naphthyridine moiety is not part of a tricyclic group.
- R 1 is alkoxy or halogen; W is CH or N; A is O or NH; B is CO or (CH 2 ) q ;
- G is a group having one of the three formulae below
- Q represents O or S
- Z represents CH or N (notably CH)
- R 2 represents halogen (notably fluorine) and R 3 represents alkyl
- m is 0 or 1
- n is 1 or 2
- p is 0 or 1, provided m and p are not each 0
- q is 1 or 2
- salts in particular pharmaceutically acceptable salts of compounds of formula I.
- alkyl refers to a saturated straight or branched chain alkyl group containing from one to four carbon atoms.
- Representative examples of alkyl groups include methyl, ethyl, propyl, ⁇ o-propyl, n-butyl, ⁇ o-butyl, sec-butyl and tert-butyh
- (Ci-C x )alkyl (x being an integer) refers to a straight or branched chain alkyl group containing 1 to x carbon atoms.
- alkoxy refers to a saturated straight or branched chain alkoxy group containing from one to four carbon atoms. Representative examples of alkoxy groups include methoxy, ethoxy, propoxy, ⁇ o-propoxy, n-butoxy, ⁇ o-butoxy, sec-butoxy and tert-butoxy.
- (Ci-C x )alkoxy refers to a straight or branched chain alkoxy group containing 1 to x carbon atoms.
- halogen refers to fluorine, chlorine, bromine or iodine, preferably to fluorine or chlorine.
- a bond interrupted by a wavy line shows a point of attachment of the radical drawn to the rest of the molecule.
- the compounds of formula I according to this invention may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms.
- the compounds of formula I may thus be present as mixtures of stereoisomers or, preferably, as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
- the present invention also includes isotopically labelled, especially 2 H (deuterium) labelled compounds of formula I, which compounds are identical to the compounds of formula I except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
- Isotopically labelled, especially 2 H (deuterium) labelled compounds of formula I and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2 H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile.
- the compounds of formula I are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-variant, the compounds of formula I are not isotopically labelled at all. Isotopically labelled compounds of formula I may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
- pharmaceutically acceptable salts refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
- room temperature refers to a temperature of 25°C.
- the term "about” placed before a numerical value "X” refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X.
- the term “about” placed before a temperature “Y” refers in the current application to an interval extending from the temperature Y minus 1O 0 C to Y plus 1O 0 C, and preferably to an interval extending from Y minus 5 0 C to Y plus 5 0 C.
- the invention furthermore relates to compounds of formula I as defined in embodiment i) that are also compounds of formula Ip
- R 1 is alkoxy or halogen
- W is CH or N
- the invention relates to compounds of formula I as defined in embodiment i) that are also compounds of formula I CE
- R 1 is alkoxy (especially methoxy);
- W is CH or N
- A is O or NH
- B is CO or (CH 2 ) q ;
- G is a group of the formula
- R 2 represents halogen (notably fluorine) and R 3 represents alkyl (notably methyl); m is 0 and n is 1 or 2 or m is 1 and n is 1 ; p is 0 or 1, provided m and p are not each 0; and q is 1 or 2; and to salts (in particular pharmaceutically acceptable salts) of compounds of formula I CE -
- the invention furthermore relates to compounds of formula I P as defined in embodiment ii) that are also compounds of formula I CEP
- R 1 is alkoxy (especially methoxy);
- W is CH or N
- A is O or NH
- G is a group of the formula
- the compounds of formula I as defined in one of embodiments i) to iv) above or their salts (among which the pharmaceutically acceptable salts will be preferred) will be such that R 1 is (Ci-C 4 )alkoxy or fluorine (and preferably (Ci-C3)alkoxy, in particular methoxy or ethoxy, especially methoxy) in the case of compounds of formula I as defined in embodiment i) or iii) or salts thereof, or such that R 1 is (Ci-C4)alkoxy (and preferably (Ci-Cs)alkoxy, in particular methoxy or ethoxy, especially methoxy) in the case of compounds of formula I as defined in embodiment ii) or iv) or salts thereof, or such that R 1 is (Ci-C4)alkoxy (and preferably (Ci-Cs)alkoxy, in particular methoxy or ethoxy, especially methoxy) in the case of compounds of formula I as defined in embodiment ii) or i
- Another embodiment of this invention relates to the compounds of formula I as defined in one of embodiments i) to v) above or their salts (among which the pharmaceutically acceptable salts will be preferred) wherein W is CH.
- Yet another embodiment of this invention relates to the compounds of formula I as defined in one of embodiments i) to v) above or their salts (among which the pharmaceutically acceptable salts will be preferred) wherein W is N.
- the compounds of formula I as defined in one of embodiments i) to vii) above or their salts will be such that A is O (and notably such that A is O and p, if present, is 1).
- the compounds of formula I as defined in one of embodiments i) to vii) above or their salts will be such that A is NH (and notably such that A is NH and each of m and p, if present, is 1).
- the compounds of formula I as defined in one of embodiments i) to ix) above or their salts (among which the pharmaceutically acceptable salts will be preferred) will be such that p, if present, is 0 and m is 1.
- the compounds of formula I as defined in one of embodiments i) to ix) above or their salts (among which the pharmaceutically acceptable salts will be preferred) will be such that p, if present, is 1.
- One sub-embodiment of embodiment xi) relates to the compounds of formula I as defined in embodiment xi) above or their salts (among which the pharmaceutically acceptable salts will be preferred) wherein m is 0, n is 1 and B, if present, is (CH 2 ) q , q being 1.
- xiii) Another sub-embodiment of embodiment xi) relates to the compounds of formula I as defined in embodiment xi) above or their salts (among which the pharmaceutically acceptable salts will be preferred) wherein m is 0, n is 2 and B, if present, is (CH 2 ) q , q being 1.
- embodiment xiv Yet another sub-embodiment of embodiment xi) relates to the compounds of formula I as defined in embodiment xi) above or their salts (among which the pharmaceutically acceptable salts will be preferred) wherein m is 1, n is 1 and B, if present, is (CH 2 ) q , q being 1.
- embodiment xi) Yet a further sub-embodiment of embodiment xi) relates to the compounds of formula I as defined in embodiment xi) above or their salts (among which the pharmaceutically acceptable salts will be preferred) wherein B, if present, is (CH 2 ) q , q being 2 (and notably such that m is 0, n is 2 and B, if present, is (CH 2 ) q , q being 2).
- the compounds of formula I as defined in embodiment i) or iii) above or in any of embodiments v) to xi) taken together with embodiment i) or iii) above, or their salts (among which the pharmaceutically acceptable salts will be preferred), will be such that B is CO.
- the compounds of formula I as defined in one of embodiments i) to xv) above or their salts (among which the pharmaceutically acceptable salts will be preferred) will be such that B, if present, is (CH 2 ) q .
- xviii One sub-embodiment of embodiment xvii) relates to the compounds of formula I as defined in embodiment xvii) above or their salts (among which the pharmaceutically acceptable salts will be preferred) wherein q is 1 (and notably such that n is 1 and q is 1).
- xix The other sub-embodiment of embodiment xvii) relates to the compounds of formula I as defined in embodiment xvii) above or their salts (among which the pharmaceutically acceptable salts will be preferred) wherein q is 2.
- the compounds of formula I as defined in embodiments i) to xix) above or their salts (among which the pharmaceutically acceptable salts will be preferred) will be such that G represents a group of the formula
- R 2 represents halogen (preferably fluorine) and R 3 represents alkyl (preferably methyl).
- R 3 represents alkyl (preferably methyl).
- a further object of this invention thus relates to the following compounds of formula I as defined in one of embodiments i) to iv) :
- a further object of this invention thus relates to the following compounds of formula I as defined in embodiment i) or iii):
- the invention further relates to the compounds of formula I as defined in embodiment i) or iii) which are selected from the group consisting of the compounds listed in embodiment xxxiv) and the compounds listed in embodiment xxxvi), as well as to the salts (in particular the pharmaceutically acceptable salts) of such compounds.
- the invention moreover relates to the compounds of formula I as defined in embodiment i) or iii) which are selected from the group consisting of the compounds listed in embodiment xxxv) and the compounds listed in embodiment xxxvii), as well as to the salts (in particular the pharmaceutically acceptable salts) of such compounds.
- the compounds of formula I according to the invention are suitable for the use as chemotherapeutic active compounds in human and veterinary medicine and as substances for preserving inorganic and organic materials in particular all types of organic materials for example polymers, lubricants, paints, fibres, leather, paper and wood.
- the compounds of formula I according to the invention are particularly active against bacteria and bacteria-like organisms. They are therefore particularly suitable in human and veterinary medicine for the prophylaxis and chemotherapy of local and systemic infections caused by these pathogens as well as disorders related to bacterial infections comprising pneumonia, otitis media, sinusitis, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Enterococcus faecalis, E.faecium, E. casseliflavus, S. epidermidis, S.
- haemolyticus or Peptostreptococcus spp.
- pharyngitis rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Corynebacterium diphtheriae, or Actinobacillus haemolyticum
- respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae
- blood and tissue infections including endocarditis and osteomyelitis, caused by S. aureus, S. haemolyticus, E. faecalis, E.
- faecium E. durans, including strains resistant to known antibacterials such as, but not limited to, beta-lactams, vancomycin, aminoglycosides, quinolones, chloramphenicol, tetracyclines and macrolides; uncomplicated skin and soft tissue infections and abscesses, and puerperal fever related to infection by Staphylococcus aureus, coagulase-negative staphylococci (i.e., S. epidermidis, S.
- Streptococcus pyogenes Streptococcus agalactiae, Streptococcal groups C-F (minute colony streptococci), viridans streptococci, Corynebacterium minutissimum, Clostridium spp., or Bartonella henselae
- uncomplicated acute urinary tract infections related to infection by Staphylococcus aureus, coagulase-negative staphylococcal species, or Enterococcus spp.
- urethritis and cervicitis sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Neiserria gonorrheae
- aureus food poisoning and toxic shock syndrome
- Groups A, B, and C streptococci ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by Chlamydia trachomatis, Neisseria gonorrhoeae, S. aureus, S. pneumoniae, S. pyogenes, H.
- MAC Mycobacterium avium complex
- chelonei gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp.; odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; and atherosclerosis or cardiovascular disease related to infection by Helicobacter pylori or Chlamydia pneumoniae.
- the compounds of formula I according to the present invention are further useful for the preparation of a medicament for the treatment of infections that are mediated by bacteria such as E. coli, Klebsiella pneumoniae and other Enterobacteriaceae, Acinetobacter spp. including Acinetobacter baumanii, Stenothrophomonas maltophilia, Neisseria meningitidis, Bacillus cereus, Bacillus anthracis, Clostridium difficile, Corynebacterium spp., Propionibacterium acnes and bacteroide spp.
- bacteria such as E. coli, Klebsiella pneumoniae and other Enterobacteriaceae, Acinetobacter spp. including Acinetobacter baumanii, Stenothrophomonas maltophilia, Neisseria meningitidis, Bacillus cereus, Bacillus anthracis, Clostridium difficile, Corynebacterium spp., Propionibacterium acnes and bacter
- the compounds of formula I according to the present invention are further useful to treat protozoal infections caused by Plasmodium malaria, Plasmodium falciparum, Toxoplasma gondii, Pneumocystis carinii, Trypanosoma brucei and Leishmania spp.
- the present list of pathogens is to be interpreted merely as examples and in no way as limiting.
- the compounds of fomula I according to this invention may be used for the preparation of a medicament, and are suitable, for the prevention or treatment (and notably for the treatment) of a bacterial infection.
- One aspect of this invention therefore relates to the use of a compound of formula I according to one of embodiments i) to xxxix), or of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment (and notably for the treatment) of a bacterial infection.
- Another aspect of this invention relates to a compound of formula I according to one of embodiments i) to xxxix), or of a pharmaceutically acceptable salt thereof, for the prevention or treatment (and notably for the treatment) of a bacterial infection.
- the compounds of formula I according to one of embodiments i) to xxxix), or the pharmaceutically acceptable salts thereof may be used for the preparation of a medicament, and are suitable, for the prevention or treatment (and notably for the treatment) of a bacterial infection selected from the group consisting of respiratory tract infections, otitis media, meningitis, skin and soft tissue infections (whether complicated or uncomplicated), pneumonia (including hospital acquired pneumonia), bacteremia, endocarditis, intraabdominal infections, gastrointestinal infections, Clostridium difficile infections, urinary tract infections, sexually transmitted infections, foreign body infections, osteomyelitis, lyme disease, topical infections, opthalmological infections, tuberculosis and tropical diseases (e.g.
- a bacterial infection selected from the group consisting of respiratory tract infections, otitis media, meningitis, skin and soft tissue infections (whether complicated or uncomplicated), pneumonia (including hospital acquired pneumonia), bacteremia, endocarditis, intraabdominal infections, gastrointestinal infections, Clos
- a bacterial infection selected from the group consisting of respiratory tract infections, otitis media, meningitis, skin and soft tissue infections (whether complicated or uncomplicated), pneumonia (including hospital acquired pneumonia) and bacteremia.
- bacterial infections can also be treated using compounds of formula I (or pharmaceutically acceptable salts thereof) in other species like pigs, ruminants, horses, dogs, cats and poultry.
- the present invention also relates to pharmacologically acceptable salts and to compositions and formulations of compounds of formula I. Any reference to a compound of formula I is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.
- a pharmaceutical composition according to the present invention contains at least one compound of formula I (or a pharmaceutically acceptable salt thereof) as the active agent and optionally carriers and/or diluents and/or adjuvants, and may also contain additional known antibiotics.
- the compounds of formula I and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parenteral administration.
- compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula I or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
- Another aspect of the invention concerns a method for the prevention or the treatment (and notably for the treatment) of a bacterial infection in a patient comprising the administration to said patient of a pharmaceutically active amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
- any preferences and (sub-)embodiments indicated for the compounds of formula I (whether for the compounds themselves, salts thereof, compositions containing the compounds or salts thereof, uses of the compounds or salts thereof, etc.) apply mutatis mutandis to the compounds of formula Ip, the compounds of formula I CE and the compounds of formula I CEP -
- the compounds of formula I may also be used for cleaning purposes, e.g. to remove pathogenic microbes and bacteria from surgical instruments or to make a room or an area aseptic.
- the compounds of formula I could be contained in a solution or in a spray formulation.
- the benzyl carbamates are deprotected by hydrogenolysis over a noble metal catalyst (e.g. Pd/C or Pd(OH) 2 ZC).
- a noble metal catalyst e.g. Pd/C or Pd(OH) 2 ZC.
- the Boc group is removed under acidic conditions such as HCl in an organic solvent such as MeOH or dioxane, or TFA neat or diluted in a solvent such DCM.
- the Alloc group is removed in presence of tetrakis (triphenylphosphine)palladium(O) in presence of an allyl cation scavenger such as morpholine, dimedone or tributyltin hydride between 0 0 C and 50 0 C in a solvent such as THF.
- the JV-benzyl protected amines are deprotected by hydrogenolysis over a noble catalyst (e.g. Pd(OHyC).
- a noble catalyst e.g. Pd(OHyC).
- the N-acetyl protecting group is removed under basic conditions such as Na 2 CO 3 , LiOH or NaOH in aq. MeOH or THF, or under acidic conditions such as aq. HCl in THF.
- the Fmoc group is removed by treatment with an organic base such as piperidine or morpholine in a solvent such as DMF or THF .
- the alcohol is reacted with MsCl, TfCl or TsCl in presence of a base such as TEA in a dry aprotic solvent such as Pyr, THF or DCM between -30 0 C and 50 0 C.
- a base such as TEA
- a dry aprotic solvent such as Pyr, THF or DCM between -30 0 C and 50 0 C.
- Tf 2 O or Ms 2 O can also be used.
- These sulfonates can be reacted with sodium iodide in a ketone such as acetone or 2-butanone, in MeCN or in DMF between 40 0 C and 120 0 C delivering the corresponding iodide derivatives.
- the alcohol can be reacted with an amine or sodium azide in presence of an organic base such as DIPEA or TEA or an inorganic base such as sodium carbonate in a solvent such as DMSO or DMF between 20 0 C and 100 0 C.
- an organic base such as DIPEA or TEA
- an inorganic base such as sodium carbonate in a solvent such as DMSO or DMF between 20 0 C and 100 0 C.
- the azide can also be obtained by activation of the alcohol under Mitsunobu conditions in presence of PPh 3 and DEAD or DIAD in a solvent such as THF, DMF, DCM or DME between -20 0 C and 60 0 C as reviewed by O. Mitsunobu, in Synthesis (1981), 1 and reaction with DPPA.
- reaction technique . 3 (reductive amination): The reaction between the amine and the aldehyde or ketone is performed in a solvent system allowing the removal of the formed water through physical or chemical means (e.g. distillation of the solvent- water azeotrope or presence of drying agents such as molecular sieves, MgSO 4 or Na 2 SO 4 ).
- a solvent system consists typically in toluene, Hex, THF, DCM or DCE or in a mixture of solvents such as MeOH-DCE.
- the reaction can be catalyzed by traces of acid (usually AcOH).
- the intermediate imine is reduced with a suitable reducing agent (e.g.
- reaction is carried out between -10 0 C and 110 0 C, preferably between 0 0 C and 60 0 C.
- the reaction can also be carried out in one pot. It can also be performed in protic solvents such as MeOH or water in presence of a picoline-borane complex (Tetrahedron (2004), 60, 7899-7906).
- the amine derivative is reacted with an alkyl or alkenyl halide such as allyl iodide in presence of an inorganic base such as K 2 CO 3 or an organic base such as TEA in a solvent such as THF between 0 0 C and 80 0 C.
- an inorganic base such as K 2 CO 3 or an organic base such as TEA
- a solvent such as THF between 0 0 C and 80 0 C.
- THF a solvent
- a carbamate the reaction is performed in presence of NaH between 0 0 C and rt.
- the diol is obtained by dihydroxylation of the corresponding alkenyl derivative using a catalytic amount of osmium tetroxide in the presence a co-oxidant such as NMO in aq. solvent such as an acetone-water or DCM-water mixture (see Cha, J.K. Chem. Rev. (1995),
- the chiral cis-diols are obtained by using AD-mix ⁇ or AD-mix ⁇ in presence of methanesulfonamide in a water/2 -methyl-2-propanol mixture as described in
- the 1 ,2-aminoalcohol derivative is reacted with phosgene, diphosgene or triphosgene. This reaction is preferably carried out in a dry aprotic solvent such as DCM or THF in presence of an organic base such as TEA or Pyr and at a temperature between -30° and +40 0 C.
- a dry aprotic solvent such as DCM or THF
- an organic base such as TEA or Pyr
- the 1 ,2-aminoalcohol derivative is reacted with CDI or N,N -disuccinimidyl carbonate in a dry aprotic solvent such as DCM or THF in presence of an organic base such as TEA or Pyr and at a temperature between -30° and +80 0 C.
- reaction technique . 7 . (amine . protection) : Amines are usually protected as carbamates such as Alloc, Cbz, Boc or Fmoc. They are obtained by reacting the amine with allyl or benzyl chloroformate, di-tert-buty ⁇ dicarbonate or Fmoc chloride in presence of a base such as NaOH, TEA, DMAP or imidazole. They can also be protected as //-benzyl derivatives by reaction with benzyl bromide or chloride in presence of a base such as Na 2 CO 3 or TEA. Alternatively, TV-benzyl derivatives can be obtained through reductive amination in presence of benzaldehyde (see general reaction technique 3).
- the ester is reduced with a boron or aluminium hydride reducing agent such as LiBH 4 or LiAlH 4 in a solvent such as THF between -20 0 C and 40 0 C.
- a boron or aluminium hydride reducing agent such as LiBH 4 or LiAlH 4 in a solvent such as THF between -20 0 C and 40 0 C.
- the ester function is hydrolyzed into its corresponding acid using an alkali hydroxide such as NaOH, KOH or LiOH in water or in a mixture of water with polar protic or aprotic organic solvent such as THF or MeOH between -10 0 C and 50 0 C.
- the resulting carboxylic acid is further reduced into the corresponding alcohol using a borane derivative such as a BH 3 .
- THF complex in a solvent such as THF between -10 0 C and 40 0 C.
- the primary alcohols can be transformed into their corresponding aldehydes through oxidation under Swern (see D. Swern et al., J. Org. Chem. (1978), 43, 2480-2482) or Dess Martin (see D.B. Dess and J.C. Martin, J. Org. Chem. (1983), 48, 4155) conditions, respectively
- the esters can be transformed into their corresponding aldehydes by controlled reduction with a bulky hydride reagent such as DIBAH.
- DIBAH bulky hydride reagent
- the alcohol derivative is dissolved in THF or DMF and treated with tBuOK and the solution is heated between 60 0 C to 100 0 C for one hour.
- the reaction mixture is quenched with a sat. NH 4 Cl solution.
- the amine derivative is dissolved in NMP or DMF and treated with DIPEA or K2CO3 and the solution is heated between 6O 0 C to 100 0 C for one hour.
- the reaction mixture is quenched with a sat. NH 4 Cl solution.
- reaction technique 1 . 3 (reduction of azides . into . amines) : The azides are hydrogenated over a noble metal catalyst such as Pd/C in solvent such as MeOH or EA. In case the molecule is containing an unsaturated double or triple bond, the reduction can be performed using PPh 3 in presence of water as described in J. Med. Chem. (1993), 36, 2558-68.
- General reaction technique 1 . 4 . Wittig: .
- the required phosphonium salt is treated in a solvent such as water with an inorganic base such as NaOH.
- the corresponding phosphorane is collected by filtration and dried in vacuo. It is reacted with the required aldehyde in an aprotic solvent such as THF, DCM or toluene between 0 0 C and 90 0 C.
- an aprotic solvent such as THF, DCM or toluene between 0 0 C and 90 0 C.
- the Wittig-Horner variant of the reaction can be used wherein the phosphono ester (generated from the corresponding bromide and triethylphosphite) is reacted with the adehyde in presence of a base such as NaH or NaOMe in a solvent such as ether or THF between 0 0 C and 50 0 C.
- reaction technique 1 . 5 (protection of alcohols) .
- the alcohols are protected as silyl ether (usually TBDMS or TBDPS).
- the alcohol is reacted with the required silyl chloride reagent (TBDMSCl or TBDPSCl) in presence of a base such as imidazole or TEA in a solvent such as DCM, THF or DMF between 10 0 C and 40 0 C.
- a base such as imidazole or TEA
- a solvent such as DCM, THF or DMF between 10 0 C and 40 0 C.
- Further strategies to introduce other alcohol protecting groups have been described in Protecting Groups in Organic Synthesis 3 rd Ed (1999), 23-147; T.W.Greene, P.G.M. Wuts; (Publisher: John Wiley and Sons, Inc., New York, N.Y.).
- the aromatic halide (Cl, Br, I) is reacted in presence of a palladium catalyst such as palladium (II) acetate, in presence of a dialkylphophinobiaryl ligand such as [l,l']binaphthalenyl-2-yl-di-tert-butyl-phosphane and in presence of a base such as K2CO3 or CS2CO3 between +20 0 C and +100 0 C, as described in J. Am. Chem. Soc. (2001), 123, 12202-12206.
- a palladium catalyst such as palladium (II) acetate
- a dialkylphophinobiaryl ligand such as [l,l']binaphthalenyl-2-yl-di-tert-butyl-phosphane
- a base such as K2CO3 or CS2CO3 between +20 0 C and +100 0 C, as described in J. Am. Chem. Soc
- the carboxylic acid is reacted with the amine in presence of an activating agent such as
- the carboxylic acid can be activated by conversion into its corresponding acid chloride by reaction with oxalyl chloride or thionyl chloride neat or in a solvent like DCM between -20° and +60 0 C.
- reaction technique 1 . 8 (oxidation of alcohols , into acids) :
- Alcohols can be directly oxidized into their corresponding acids by a variety of methods as described in Comprehensive Organic Transformations. A guide to Functional Group
- the compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.
- Sections a) to g) hereafter describe general methods for preparing compounds of formula I.
- the symbols A, R 1 , W, B, G, m, n, p and q have the same meanings as in formula I unless mentioned otherwise.
- a) The compounds of formula I and B is (CH2) q can be obtained by deprotecting the compounds of formula II
- A is O, NH or N-PG 0 and PG 0 and PG 1 each represent an amino protecting group such as Boc, Cbz, Fmoc or benzyl, following general reaction technique 1.
- A is O or NPG 0 , wherein PG 0 is an amino protecting group such as Cbz, Boc, Fmoc or benzyl, with the compounds of formula IV
- A is O or N-PG 0
- PG 0 is an amino protecting group such as Boc, Cbz, Fmoc or benzyl and Y represents a halogen such as iodine or bromine, or a group of the formula OSO 2 R *1 wherein R a represents methyl, trifluoromethyl or tolyl, following general reaction technique 2, with the compounds of formula VI
- the protecting group can be removed following general reaction technique 1.
- X 1 represents halogen such as fluorine or bromine according to general reaction technique 10.
- the compounds of formula VIII can be TV-protected according to general reaction technique 7, ring closed under Buchwald conditions according to general reaction technique 16 and finally JV-deprotected according to general reaction technique 1.
- X 1 represents halogen such as fluorine or bromine and PG 1 is an amino protecting group such as Boc, Cbz, Fmoc or benzyl according to general reaction technique 10 followed by removal of the amino protecting group according to general reaction technique 1.
- the compounds of formula I thus obtained may, if desired, be converted into their salts, and notably into their pharmaceutically acceptable salts.
- the enantiomers can be separated using methods known to one skilled in the art, e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Regis Whelk-O1(R,R) (10 ⁇ m) column, a Daicel ChiralCel OD-H (5-10 ⁇ m) column, or a Daicel ChiralPak IA (10 ⁇ m) or AD-H (5 ⁇ m) column.
- a chiral stationary phase such as a Regis Whelk-O1(R,R) (10 ⁇ m) column, a Daicel ChiralCel OD-H (5-10 ⁇ m) column, or a Daicel ChiralPak IA (10 ⁇ m) or AD-H (5 ⁇ m) column.
- Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of an amine such as triethylamine, diethylamine) and eluent B (hexane), at a flow rate of 0.8 to 150 mL/min.
- EtOH eluent A
- eluent B hexane
- A represents O, NH or NPG 0 and PG 0 and PG 1 represent independently from each other an amino protecting group such as Boc, Fmoc, Cbz or benzyl.
- the compounds of formula 1-1 wherein A is O or N-PG 0 can be transformed into the compounds of formula 1-3 by reaction with allyl bromide or 4-bromo-l-butene according to general reaction technique 4, followed by c ⁇ -dihydroxylation according to general reaction technique 5, followed by activation of the primary alcohol function as a mesylate according to general reaction technique 2 and ring closure into the epoxide in presence of a base such as Na 2 CO 3 or TEA.
- a base such as Na 2 CO 3 or TEA.
- the compounds of formula 1-3 wherein q is 1 might be obtained by reacting intermediates of formula 1-1 with epichlorhydrin.
- the epoxides of formula 1-3 can be further reacted with an aniline of formula G-NH 2 and the resulting amino alcohols of formula 1-4 can be transformed into the compounds of formula II wherein A is O or N-PG 0 according to general reaction technique 6. If A is N-PG 0 , the amino protecting group can be removed according to general reaction technique 1.
- the compounds of formula III and 1-1 wherein m is 1, n is 1 and p is 1 can be prepared as described in Scheme 2 hereafter.
- X 1 and X 2 represent independently from each other halogen such as fluorine (e.g. for X 1 ) or bromine (e.g. for X 2 ), R b represents alkyl or benzyl and PG 1 represents an amino protecting group such as Cbz, Boc, Fmoc or benzyl.
- the intermediates of formula II- 1 can be reacted with the ⁇ -alanine derivatives of formula II-2 (e.g. JV-(tert-butoxycarbonyl)- ⁇ -alanine methyl ester; commercial) in the presence of a strong base such as LiHDMS below -50 0 C in a dry solvent such as THF.
- the resulting amino ester derivatives of formula II-3 can be reduced into the corresponding alcohol derivatives of formula II-4 according to general reaction technique 8.
- the amino protecting group can be removed according to general reaction technique 1 and the resulting amino alcohols of formula II-5 can then be cyclised according to general reaction techniques 10a or 16.
- the compounds of formula 1-1 can be obtained by protection of the compounds of formula III according to general reaction technique 7. Alternatively they can be obtained by cyclising the intermediates of formula II-4 in presence of a base such as K2CO3 or NaH.
- the compounds of formula 1-1 wherein A is NH or NPG 0 can be obtained by transforming the compounds of formula II-4 into their corresponding mesylates and amines of formula II-6 according to general reaction techniques 2 and 13. These latter intermediates can be cyclised according to general reaction technique 10 or 10a, affording the compounds of formula 1-1 wherein A is NH.
- the compounds of formula 1-1 wherein A is NPG 0 can be obtained by subsequent protection according to general reaction technique 7.
- R c represents alkyl
- X 1 represents halogen such as fluorine, chlorine or bromine
- PG 0 and PG 2 each represent an amino protecting group such as Cbz, Boc, Fmoc or benzyl.
- the esters of formula III-l can be reacted with bromoacetonitrile in presence of a strong base such as LiHDMS below -50 0 C in a dry solvent such as THF.
- a strong base such as LiHDMS below -50 0 C in a dry solvent such as THF.
- the resulting nitrile derivatives of formula III-2 can be reduced with LAH in presence of AICI3 affording the amino alcohols of formula III-3 which can then be cyclised into the derivatives of formula III according to general reaction technique 10.
- the amine function of the compounds of formula III-3 can be protected according to general reaction technique 7 and the alcohol function can be transformed into the corresponding amine according to general reaction techniques 2 and 13 and further be cyclised according to general reaction techniques 10a or 16.
- R c represents alkyl
- X 1 represents halogen such as fluorine, bromine or chlorine
- PG 3 represents an amino protecting group such as Cbz, Boc, Fmoc or benzyl.
- the intermediates of formula III-l can be reacted with ⁇ /-(bromomethyl)phthalimide (commercial) in presence of a strong base such as LiHDMS below -50 0 C in a dry solvent such as THF.
- a strong base such as LiHDMS below -50 0 C in a dry solvent such as THF.
- the resulting phthalimido derivatives of formula IV-I can be reacted with a hydrazine derivative such as hydrazine hydrate or //-methyl hydrazine in a solvent such as ethanol or DCE between 40 0 C and 80 0 C affording the corresponding amino derivatives of formula IV-2, which can be protected following general reaction technique 7.
- the intermediates of formula IV-3 can be reduced following general reaction technique 8, the protecting group can be removed following general reaction technique 1, and the compounds can then be ring closed using general reaction technique 10 to yield the desired compounds of formula III wherein A is O.
- the compounds of formula III wherein A is NH or NPG 0 can be obtained by transforming the alcohol derivatives of formula IV-4 into the corresponding amino derivatives of formula IV-6 according to general reaction techniques 2 and 13 followed by cyclisation according general reaction technique 10.
- the resulting derivatives of formula IV-7 wherein A is NH can optionally be protected according to general reaction technique 2 and finally the protecting group on the primary amine can be removed according to general reaction technique 1.
- the compounds of formula V can also be transformed into the corresponding amine derivatives of formula III wherein m and n are each 1 and p is 0 according to general reaction techniques 2 and 13.
- PG 0 represents an amino protecting group such as Boc, Fmoc, Cbz or benzyl and X 1 represents halogen such as fluorine or bromine.
- X 1 represents halogen such as fluorine or bromine.
- the compounds of formula V wherein A is O, m is 0 or 1 and n is 1 and the compounds of formula VII wherein m is 0 or 1 and n is 1 can be obtained from the corresponding alcohol derivatives of formula V-I by either activation of the alcohol function or oxidation into the corresponding aldehydes, following general reaction techniques 2 and 9 respectively.
- the compounds of formula V wherein A is N-PG 0 , m is 0 or 1 and n is 1 can be obtained by activation of the alcohol function of the derivatives of formula V-3 following general reaction technique 2.
- the starting alcohols of formula V-3 can be obtained from the precursors of formula V-2 according to the general reaction technique 7.
- the compounds of formula V-2 can be obtained from compounds of formula II-5 or IV-5 by cyclisation using general reaction technique 10a or 16.
- the compounds of formula V-2 can also be obtained from the corresponding protected alcohols, obtained from the compounds of formula II-5 or IV-6 following general reaction technique 15, by intramolecular cyclisation according to the general reaction technique 16, followed by removal of the alcohol protection following general reaction technique 11.
- PG 0 represents an amino protecting group such as Boc, Fmoc, Cbz or benzyl
- PG 4 represents a hydroxy protecting group such as TBDMS or OCOR g wherein R g is alkyl, R f represents alkyl or benzyl and X 1 represents halogen such as fluorine.
- the compounds of formula V wherein A is N-PG 0 can be obtained from the alcohol derivatives of formula V-4 after sequential protection of the alcohol function following general reaction technique 15 and reduction of the ester function following general reaction technique 8.
- the resulting alcohols derivatives of formula V-5 can be transformed into the corresponding amine derivatives of formula V-6 following general reaction techniques 2 and 13.
- the amine derivatives of formula V-6 can be cyclised into the derivatives of formula V-7 by treatment with a base such as DIPEA or K 2 CO 3 (if W is N), or following general reaction technique 16 (if W is CH).
- the tricyclic derivatives of formula V-7 can be transformed into the compounds of formula V-8 following general reaction technique 7 and the alcohol protecting group can be removed following general reaction technique 11.
- the resulting alcohol derivatives of formula V-9 can then be transformed into the desired derivatives of formula V wherein A is NPG 0 following general reaction technique 2.
- the derivatives of formula V-5 can also be directly cyclised using general reaction technique 10a or 16, affording, after removal of the alcohol protecting group following general reaction technique 11, the intermediate derivatives of formula V-IO which can be further transformed into the derivatives of formula V wherein A is O using general reaction technique 2.
- A represents O, NH or N-PG 0 wherein PG 0 represents an amino protecting group such as Boc, Cbz, Fmoc or benzyl, PG 4 represents a hydroxy protecting group such as TBDMS or OCOR g wherein R g is alkyl and X 1 represents halogen such as chlorine.
- PG 0 represents an amino protecting group such as Boc, Cbz, Fmoc or benzyl
- PG 4 represents a hydroxy protecting group such as TBDMS or OCOR g wherein R g is alkyl and X 1 represents halogen such as chlorine.
- the triflate derivatives of formula V-I l (e.g. trifluoromethanesulfonic acid 3-chloro- 6-methoxy-[l,5]naphthyridin-4-yl ester; prepared according to WO 2004/058144) can be transformed into the corresponding allyl derivatives of formula V- 12 after reaction with allyltributyltin in presence of a cross coupling palladium catalyst such as Pd(PPtLs) 4 .
- These intermediates can be transformed into the corresponding diols of formula V- 13 using general reaction technique 5.
- the primary alcohol function of the latter can be protected using general reaction technique 15, affording the intermediates of formula V- 14 wherein A is O.
- the intermediates of formula V- 14 can be cyclised into the derivatives of formula V- 15 using general reaction technique 10 if A is O, or general reaction technique 1 Oa or 16 if A is NH.
- an amino protecting group (PG 0 ) should be introduced using general reaction technique 7.
- the alcohol function of the intermediates of formula V- 15 can be activated using general reaction technique 2, affording the intermediates of formula V wherein n is 1.
- the intermediates of formula V wherein n is 2 can be obtained by reduction of the corresponding aldehydes of formula VII wherein n is 2 using general reaction technique 8 followed by activation of the alcohol using general reaction technique 2.
- the compounds of formula VII can be obtained by oxidation of the corresponding alcohol derivatives of formulae V-I, V-3, V-9, V-IO and V- 15 using general reaction technique 9 or, in the case of compounds of formula VII wherein m is 1, n is 2 and p is 0, by reduction of the nitrile derivatives of formula IV-8 with DIBAH.
- X 1 is a halogen such as fluorine, chlorine or bromine
- PG 1 is an amino protecting group such as Boc or Cbz
- PG 4 is a hydroxy protecting group such as TBDMS.
- the derivatives of formula VI-I can be transformed into the corresponding derivatives of formula VI-2 following the same methods as described in Scheme 1 for the preparation of compounds of formula II.
- the compounds of formula VIII wherein B is (CH2) q can then be obtained by deprotection of compounds of formula VI-2 using general reaction techniques 1 and 11.
- the compounds of formula VIII wherein B is CO can be obtained by removing the amino protecting group from the abovementioned compounds of formula VI-I using general reaction technique 1 followed by formation of the corresponding amide by reaction with the compounds of formula X according to general reaction technique 17.
- the compounds of formula VIII can then be obtained by deprotection of compounds of formula VI-2 using general reaction technique 11.
- PG 5 represents a hydroxy protecting group such as TBDMS or OCOR g wherein R g is alkyl
- PG 6 is COOR h wherein R h is alkyl or benzyl and X represents a halogen such as iodine or bromine, or a group of the formula OSO 2 R *1 wherein R a represents methyl, trifluoromethyl or tolyl.
- epoxides of formula VII-I wherein PG 5 is OCOR g e.g. glycidyl butyrate, commercial; or 3,4-epoxybutyl butyrate, prepared according to J. Am. Chem. Soc. (2005), 127(32), 11426-11435) can be reacted with the carbamates of formula GNHPG 6 (wherein PG 6 represents COOMe, Cbz or Boc) according to general reaction technique 12, affording the oxazolidinones of formula VII-4.
- the epoxides of formula VII-I wherein PG 5 is a silyl protecting group e.g.
- glycidyl te/t-butyldimethylsilyl ether can be reacted with the aniline derivatives of formula GNH 2 affording the amino alcohol derivatives of formula VII-2.
- These aminoalcohols can be transformed into the oxazolidinones of formula VII-3 according to general reaction technique 6 and the hydroxy protecting group can then be removed according to general reaction technique 11 to afford the compounds of formula VII-4.
- the alcohols can be sequentially transformed into the corresponding derivatives of formula IV wherein X is OMs, OTs, OTf or I and into the corresponding azide derivatives of formula VII-5 using general technique 2.
- the amine derivatives of formula VI can then be obtained after reduction of azide derivatives of formula VII-5 according to general reaction technique 13.
- the acids of formula X can be obtained by oxidation of the corresponding alcohols of formula VII-4 wherein q is 1 using general reaction technique 18.
- the compounds of formula IX can be obtained by protecting the amine function of compounds of formula VIII wherein B is (CH2) q according to general reaction technique 7, activation of the alcohol function and transformation into the corresponding azide according to general reaction technique 2 and transformation of the azide into the corresponding amine according to general reaction technique 13.
- the compounds of formula 1-1 wherein A is O can be made from compounds of formula III by protection of the primary amine according to general reaction technique 7.
- the compounds of formula 1-1 wherein A is N-PG 0 , PG 0 being Boc, Cbz or Fmoc, can be made from the compounds of formula V following sequential formation of the corresponding azide (using general reaction technique 2) and the corresponding amine (using general reaction technique 13) followed by protection of the primary amine (using general reaction technique 7).
- the compounds of formula II- 1 wherein W is CH, R 1 is OMe and X 1 is F can be prepared according to WO 2008/003690.
- the compounds of formula II-l wherein W is N, R 1 is OMe and X 1 is F can be prepared by reduction of the corresponding formyl derivatives (obtained according to WO 2006/032466) through reduction with NaBH 4 followed by reaction of the intermediate benzyl alcohols with PBr 3 .
- R is alkyl
- X is halogen such as fluorine, chlorine or bromine
- PG is an amino protecting group such as Boc, Cbz, Fmoc or benzyl
- PG 4 is a hydroxy protecting group such as TBDMS.
- the intermediates of formula VIII-4 or the compounds of formula V-4 wherein m is 0 or 1 can then be obtained by reacting the corresponding compounds of formula III-l or VIII-3 with either an aqueous formaldehyde solution or oxirane.
- the alcohol derivatives of formula V-4 or VIII-4 can be activated according to general reaction technique 2 and transformed into the corresponding amines of formula VIII-5 after reaction with sodium azide and conversion into the amine according to general reaction technique 13.
- the amine derivatives of formula VIII-5 can be protected using general reaction technique 7 and the resulting esters of formula VIII-6 can be reduced into the corresponding alcohols of formula VIII-7 using general reaction technique 8.
- the primary alcohol of the compounds of formula VIII-7 can be protected according to general reaction technique 15 , affording the compounds of formula VI- 1.
- LC-MS Sciex API 2000 with Agilent 1100 Binary Pump and DAD, using RP-C 18 based columns
- TLC TLC-plates from Merck, Silica gel 60 F254
- Compounds are purified by chromatography on Silica gel 6OA. NH 4 OH as used for CC is 25% aq. Racemates can be separated into their enantiomers as described before.
- Preferred conditions of chiral HPLC are: ChiralPak AD (4.6x25 Omm, 5 ⁇ m) column, using an isocratic mixture (eg. at a ratio of 10/90) of eluent A (EtOH, in presence of diethylamine in an amount of eg. 0.1%) and eluent B (Hex), at rt, at a flow rate of eg. 0.8 mL/min.
- Procedure D . alkylatipn of amines with . iodides
- Procedure _F Boc . protection ; To a solution of amine in DCM or THF are added TEA (1.5 eq.) and BoC 2 O (1.05 eq.). The reaction is stirred at rt until completion of the reaction. The reaction mixture is then concentrated under reduced pressure.
- PPh 3 (143 mg, 0.54 mmol) was dissolved in THF (2 mL) and then cooled to 0 0 C. DIAD (116 mg, 0.54 mmol) was then added via a syringe at 0 0 C. After the solution was stirred for 15 min (yellow suspension), a solution of intermediate 5.i (88 mg, 0.36 mmol) in THF (1 mL) was slowly added, followed immediately by the addition of DPPA (151 mg, 0.54 mmol). The reaction mixture was allowed to warm to rt and stirred for 4 h. The mixture was concentrated and the residue was filtered over a short pad of silica gel using EA as eluent.
- Example 9 6-((R>5- ⁇ [2-((7f5)-8-methoxy-l,2-dihydro-3-oxa-5,9-diaza- cyclopenta[fl]naphthalen-l-yl)-ethylamino]-methyl ⁇ -2-oxo-oxazolidin-3-yl)- 4H-benzo [ 1 ,4] thiazin-3-one:
- Example 10 6-((R)-5- ⁇ [2-((RS)-8-methoxy- 1 ,2-dihydro-3-oxa-5,9-diaza- cyclopenta[fl]naphthalen-l-yl)-ethylamino]-methyl ⁇ -2-oxo-oxazolidin-3-yl)- 4H-benzo [1 ,4] oxazin-3-one:
- Example 12 6-((5)-5- ⁇ [2-((RS)-8-methoxy-l,2-dihydro-3-oxa-5,9-diaza- cyclopenta[fl]naphthalen-l-yl)-ethylamino]-methyl ⁇ -2-oxo-oxazolidin-3-yl)- 4H-benzo [ 1 ,4] thiazin-3-one:
- Example 13 6-((R)S- ⁇ 2- [2-((ftS)-8-methoxy- 1 ,2-dihydro-3-oxa-5,9-diaza- cyclopenta[fl]naphthalen-l-yl)-ethylamino]-ethyl ⁇ -2-oxo-oxazolidin-3-yl)- 4H-benzo [ 1 ,4] thiazin-3-one:
- Example 14 6-((R)-5- ⁇ 2-[((R5)-8-methoxy-l,2-dihydro-3-oxa-5,9-diaza- cyclopenta[fl]naphthalen-l-ylmethyl)-amino]-ethyl ⁇ -2-oxo-oxazolidin-3-yl)- 4H-benzo [ 1 ,4] thiazin-3-one:
- Example 15 6-((S)S- ⁇ 2- [((RS)-8-methoxy-l ,2-dihydro-3-oxa-5,9-diaza- cyclopenta[fl]naphthalen-l-ylmethyl)-amino]-ethyl ⁇ -2-oxo-oxazolidin-3-yl)- 4H-benzo [ 1 ,4] thiazin-3-one:
- T3P 0 (114 mg; 0.11 mL; 50% in EA) was added at 0 0 C to a solution of (55)-3-(2,3-dihydro-l,4-benzodioxin-6-yl)-2-oxo-5-oxazolidinecarboxylic acid (43 mg; prepared according to WO 2008/126024), intermediate 9.iii (40 mg) and DIPEA (56 ⁇ L) in DMF (1 mL). The mixture was allowed to reach rt and was further stirred at rt temperature for 2 h. Water was added and the mixture was twice extracted with EA. The org. layers were washed with water and aq. citric acid (10%). The aq.
- Example 17 6-((R)-5- ⁇ [((R5)-8-methoxy-l,2-dihydro-3-oxa-5,9-diaza- cyclopenta[fl]naphthalen-2-ylmethyl)-amino]-methyl ⁇ -2-oxo-oxazolidin-3-yl)- 4H-benzo [ 1 ,4] thiazin-3-one:
- Second eluting compound (25)-4-(tert-butyl-dimethyl-silanyloxy)-butane-l, 2-diol (colourless oil, 24.9 g, 43% yield):
- Example 19 6-((R)-5- ⁇ 2-[((R5)-8-methoxy-l,2-dihydro-3-oxa-5,9-diaza- cyclopenta[fl]naphthalen-2-ylmethyl)-amino]-ethyl ⁇ -2-oxo-oxazolidin-3-yl)- 4H-benzo [ 1 ,4] thiazin-3-one:
- MICs Minimum inhibitory concentrations
- Example compounds were tested against several Gram positive and Gram negative bacteria such as S. aureus, E. faecalis, S. pneumoniae, M. catarrhalis, A. baumanii, E.coli or P. aeruginosa.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009278791A AU2009278791A1 (en) | 2008-08-04 | 2009-08-03 | Tricyclic alkylaminomethyloxazolidinone derivatives |
CA2731365A CA2731365A1 (en) | 2008-08-04 | 2009-08-03 | Tricyclic alkylaminomethyloxazolidinone derivatives |
JP2011521669A JP2011529960A (en) | 2008-08-04 | 2009-08-03 | Tricyclic alkylaminomethyloxazolidinone derivatives |
BRPI0916571A BRPI0916571A2 (en) | 2008-08-04 | 2009-08-03 | alkylaminomethyloxazolidinone tricyclic derivative compound, medicament and pharmaceutical composition containing it and use of the compound |
CN2009801300547A CN102105467A (en) | 2008-08-04 | 2009-08-03 | Tricyclic alkylaminomethyloxazolidinone derivatives |
ES09786776T ES2399499T3 (en) | 2008-08-04 | 2009-08-03 | Tricyclic alkylaminomethyloxazolidinone derivatives |
EP09786776A EP2321307B1 (en) | 2008-08-04 | 2009-08-03 | Tricyclic alkylaminomethyloxazolidinone derivatives |
MX2011000968A MX2011000968A (en) | 2008-08-04 | 2009-08-03 | Tricyclic alkylaminomethyloxazolidinone derivatives. |
US13/057,650 US8466168B2 (en) | 2008-08-04 | 2009-08-03 | Tricyclic alkylaminomethyloxazolidinone derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IBPCT/IB2008/053112 | 2008-08-04 | ||
IB2008053112 | 2008-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010015985A1 true WO2010015985A1 (en) | 2010-02-11 |
Family
ID=41213177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/053356 WO2010015985A1 (en) | 2008-08-04 | 2009-08-03 | Tricyclic alkylaminomethyloxazolidinone derivatives |
Country Status (12)
Country | Link |
---|---|
US (1) | US8466168B2 (en) |
EP (1) | EP2321307B1 (en) |
JP (1) | JP2011529960A (en) |
KR (1) | KR20110036938A (en) |
CN (1) | CN102105467A (en) |
AU (1) | AU2009278791A1 (en) |
BR (1) | BRPI0916571A2 (en) |
CA (1) | CA2731365A1 (en) |
ES (1) | ES2399499T3 (en) |
MX (1) | MX2011000968A (en) |
RU (1) | RU2011108008A (en) |
WO (1) | WO2010015985A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012108376A1 (en) | 2011-02-07 | 2012-08-16 | 第一三共株式会社 | Amino group-containing pyrrolidinone derivative |
WO2012171860A1 (en) | 2011-06-17 | 2012-12-20 | Basilea Pharmaceutica Ag | Tricyclic antibiotics |
WO2013021363A1 (en) * | 2011-08-11 | 2013-02-14 | Actelion Pharmaceuticals Ltd | Quinazoline-2,4-dione derivatives |
WO2014024056A1 (en) | 2012-08-06 | 2014-02-13 | Daiichi Sankyo Company, Limited | Pyrrolidine derivatives with antibacterial properties |
WO2014170821A1 (en) * | 2013-04-16 | 2014-10-23 | Actelion Pharmaceuticals Ltd | Antibacterial biaromatic derivatives |
US8927541B2 (en) | 2009-12-18 | 2015-01-06 | Basilea Pharmaceutica Ag | Tricyclic antibiotics |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102164915A (en) * | 2008-10-10 | 2011-08-24 | 埃科特莱茵药品有限公司 | 2-benzothiophenyl-and 2-naphthyl-Oxazolidinones and their azaisostere analogues as antibacterial agents |
CN103420996B (en) * | 2013-09-07 | 2015-06-24 | 吉首大学 | Benzopyrone-amine methyl-oxazolidinone compounds and preparation method and application of benzopyrone-amine methyl-oxazolidinone compounds |
AR102256A1 (en) * | 2014-10-15 | 2017-02-15 | Actelion Pharmaceuticals Ltd | ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH REPLACEMENT OF AMINOALCOXI |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040198755A1 (en) * | 2001-05-25 | 2004-10-07 | Dartois Catherine Genevieve Yvette | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials |
US20060205719A1 (en) * | 2003-04-08 | 2006-09-14 | Morphochem Aktiengesellschaft Fur | Novel compounds having an antibacterial activity |
WO2008026172A1 (en) * | 2006-08-30 | 2008-03-06 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
WO2008126024A2 (en) * | 2007-04-11 | 2008-10-23 | Actelion Pharmaceuticals Ltd | Oxazolidinone antibiotic derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR042486A1 (en) | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | QUINOLINE AND NAFTIRIDINE COMPOSITE HALOSUSTITUDED IN POSITION 3, PROCEDURE TO PREPARE THE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION. |
JP4887297B2 (en) | 2004-09-24 | 2012-02-29 | アクテリオン ファーマシューティカルズ リミテッド | New bicyclic antibiotics |
US20070102311A1 (en) | 2005-10-08 | 2007-05-10 | Kevin Kirtz | Media storage container with media cartridge page |
ES2340531T3 (en) | 2005-10-21 | 2010-06-04 | Glaxo Group Limited | PERI-CONDENSED TRICYCLES USEFUL AS ANTIBACTERIAL AGENTS. |
GB0608263D0 (en) | 2006-04-26 | 2006-06-07 | Glaxo Group Ltd | Compounds |
GB0613208D0 (en) | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
CL2008001002A1 (en) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION. |
-
2009
- 2009-08-03 MX MX2011000968A patent/MX2011000968A/en not_active Application Discontinuation
- 2009-08-03 ES ES09786776T patent/ES2399499T3/en active Active
- 2009-08-03 AU AU2009278791A patent/AU2009278791A1/en not_active Abandoned
- 2009-08-03 BR BRPI0916571A patent/BRPI0916571A2/en not_active IP Right Cessation
- 2009-08-03 WO PCT/IB2009/053356 patent/WO2010015985A1/en active Application Filing
- 2009-08-03 CN CN2009801300547A patent/CN102105467A/en active Pending
- 2009-08-03 EP EP09786776A patent/EP2321307B1/en not_active Not-in-force
- 2009-08-03 RU RU2011108008/04A patent/RU2011108008A/en not_active Application Discontinuation
- 2009-08-03 KR KR1020117003638A patent/KR20110036938A/en not_active Application Discontinuation
- 2009-08-03 US US13/057,650 patent/US8466168B2/en not_active Expired - Fee Related
- 2009-08-03 JP JP2011521669A patent/JP2011529960A/en active Pending
- 2009-08-03 CA CA2731365A patent/CA2731365A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040198755A1 (en) * | 2001-05-25 | 2004-10-07 | Dartois Catherine Genevieve Yvette | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials |
US20060205719A1 (en) * | 2003-04-08 | 2006-09-14 | Morphochem Aktiengesellschaft Fur | Novel compounds having an antibacterial activity |
WO2008026172A1 (en) * | 2006-08-30 | 2008-03-06 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
WO2008126024A2 (en) * | 2007-04-11 | 2008-10-23 | Actelion Pharmaceuticals Ltd | Oxazolidinone antibiotic derivatives |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9120822B2 (en) | 2009-12-18 | 2015-09-01 | Basilea Pharmaceutica Ag | Tricyclic antibiotics |
US8927541B2 (en) | 2009-12-18 | 2015-01-06 | Basilea Pharmaceutica Ag | Tricyclic antibiotics |
WO2012108376A1 (en) | 2011-02-07 | 2012-08-16 | 第一三共株式会社 | Amino group-containing pyrrolidinone derivative |
US8952010B2 (en) | 2011-02-07 | 2015-02-10 | Daiichi Sankyo Company, Limited | Amino group-containing pyrrolidinone derivative |
CN103635474A (en) * | 2011-06-17 | 2014-03-12 | 巴斯利尔药物股份公司 | Tricyclic antibiotics |
WO2012171860A1 (en) | 2011-06-17 | 2012-12-20 | Basilea Pharmaceutica Ag | Tricyclic antibiotics |
CN103635474B (en) * | 2011-06-17 | 2016-04-27 | 巴斯利尔药物股份公司 | Three ring microbiotic |
US8916573B2 (en) | 2011-08-11 | 2014-12-23 | Actelion Pharmaceuticals Ltd. | Quinazoline-2,4-dione derivatives |
WO2013021363A1 (en) * | 2011-08-11 | 2013-02-14 | Actelion Pharmaceuticals Ltd | Quinazoline-2,4-dione derivatives |
WO2014024056A1 (en) | 2012-08-06 | 2014-02-13 | Daiichi Sankyo Company, Limited | Pyrrolidine derivatives with antibacterial properties |
WO2014170821A1 (en) * | 2013-04-16 | 2014-10-23 | Actelion Pharmaceuticals Ltd | Antibacterial biaromatic derivatives |
CN105143216A (en) * | 2013-04-16 | 2015-12-09 | 埃科特莱茵药品有限公司 | Antibacterial biaromatic derivatives |
US9527867B2 (en) | 2013-04-16 | 2016-12-27 | Actelion Pharmaceuticals Ltd. | Antibacterial biaromatic derivatives |
EA029361B1 (en) * | 2013-04-16 | 2018-03-30 | Идорсиа Фармасьютиклз Лтд | Antibacterial biaromatic derivatives |
CN105143216B (en) * | 2013-04-16 | 2018-04-13 | 爱杜西亚药品有限公司 | Antibacterial bis-aromatic derivative |
TWI631119B (en) * | 2013-04-16 | 2018-08-01 | 愛杜西亞製藥有限公司 | Antibacterial biaromatic derivatives |
Also Published As
Publication number | Publication date |
---|---|
EP2321307A1 (en) | 2011-05-18 |
BRPI0916571A2 (en) | 2015-11-10 |
ES2399499T3 (en) | 2013-04-01 |
JP2011529960A (en) | 2011-12-15 |
CN102105467A (en) | 2011-06-22 |
US20110136795A1 (en) | 2011-06-09 |
RU2011108008A (en) | 2012-09-10 |
AU2009278791A1 (en) | 2010-02-11 |
KR20110036938A (en) | 2011-04-12 |
CA2731365A1 (en) | 2010-02-11 |
MX2011000968A (en) | 2011-03-02 |
EP2321307B1 (en) | 2012-12-19 |
US8466168B2 (en) | 2013-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2321307B1 (en) | Tricyclic alkylaminomethyloxazolidinone derivatives | |
CA2739373C (en) | Tricyclic oxazolidinone antibiotic compounds | |
AU2008238894B2 (en) | Oxazolidinone antibiotic derivatives | |
EP2254887B1 (en) | Oxazolidinone derivatives | |
JP5349500B2 (en) | Azatric cyclic antibacterial compounds | |
EP2346862B1 (en) | 2-benzothiophenyl-and 2-naphthyl-0xaz0lidin0nes and their azaisostere analogues as antibacterial agents | |
US8193179B2 (en) | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives | |
ES2628091T3 (en) | Oxazolidinyl antibiotics | |
AU2009215247B2 (en) | Oxazolidinone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980130054.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09786776 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009786776 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2731365 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/000968 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2011521669 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13057650 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117003638 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009278791 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1449/CHENP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011108008 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2009278791 Country of ref document: AU Date of ref document: 20090803 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0916571 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110126 |